^(89)SrCl_2联合^(99)mTc-MDP治疗转移性骨癌临床疗效的系统评价

Systematic review of clinical effect of Strontium chloride combined with ^(99)mTc-methylene diphosphonate on metastatic bone cancer in China

目的评价氯化锶联合^(99)mTc-亚甲基二膦酸盐(联合组)治疗我国转移性骨癌临床疗效。方法计算机检索学术期刊网络出版总库、中国知网数据库(1994~2016年)、中国万方数据库(1999~2016年)、重庆维普中文科技期刊全文数据库(1989~2016年)及中国生物医学文献数据库(1994~2016年)数据库中关于联合组治疗我国转移性骨癌疗效的临床随机对照试验(RCT),对符合标准的RCT进行Meta分析。结果共纳入16篇RCT,1 366例患者符合纳入标准。Meta分析结果,联合组治疗转移性骨癌的骨痛疗效、控制骨转移灶疗效、生存质量与单用氯化锶(对照组)治疗比较,差异有统计学意义(P<0.05),联合组优于对照组。两组不良反应比较,差异无统计学意义(P>0.05)。结论在常规对症支持治疗的基础上,联合组治疗转移性骨癌临床疗效确切,且优于对照组。

Objective To evaluate the clinical effect of combination therapy with Strontium chloride and ^99mTc-methylene diphosphonate on metastatic bone cancer in China. Methods A comprehensive search was performed in CAJD, CNKI（1994-2016）, WANFANG（1999-2016）, VIP（1989-2016） and CB Mdisc（1994-2016） databases to collect the randomized controlled trials（RCTs） in which combined therapy with Strontium chloride and ^99mTc-methylene diphosphonate was applied to metastatic bone cancer in China. Meta-analysis was performed to analyze the RCTs. Results In the 16 RCTs which met the research standards, 1,366 patients were analyzed. The meta-analysis results suggested that, compared with the Strontium chloride group,bone pain, bone metastasis control and life quality were improved significantly in the combination therapy group（P〈0.05）; and the adverse reactions had no significant differences between the two groups（P〉0.05）.Conclusions On the basis of symptomatic and supportive treatment, the effect of combined therapy of Strontium chloride and ^99mTc-methylene diphosphonate is positive for treatment of metastatic bone cancer, and better than that of simple Strontium chloride treatment.